Arizona Tribune - Johnson & Johnson temporarily halts Covid-19 vaccine output: report

NYSE - LSE
RYCEF 0.85% 17.74 $
CMSC 1.05% 19.162 $
RBGPF 0% 75.65 $
NGG -0.36% 82.265 $
BP -3.68% 43.26 $
BTI -1.27% 58.42 $
RIO -4.61% 75.97 $
GSK -1.13% 48.69 $
CMSD 1.3% 18.885 $
BCE 0.32% 22.09 $
JRI -0.58% 10.907 $
RELX -0.18% 39.32 $
BCC 1.52% 66.145 $
AZN -1.63% 179.35 $
VOD -2.15% 14.9 $
Johnson & Johnson temporarily halts Covid-19 vaccine output: report
Johnson & Johnson temporarily halts Covid-19 vaccine output: report

Johnson & Johnson temporarily halts Covid-19 vaccine output: report

Johnson & Johnson has temporarily suspended production at a key plant manufacturing the Covid-19 vaccine, the New York Times reported Tuesday.

Text size:

The facility in the Dutch city of Leiden halted output late last year, according to the report, which cited people familiar with the decision.

J&J, without confirming or denying the report, said it has continued to fulfill delivery commitments, a company spokesman said.

The factory, which is currently making an experimental vaccine, is expected to resume production of the Covid-19 vaccine again in a "few" months, the Times reported.

J&J currently has "millions of doses of our Covid-19 vaccine in inventory," according to the J&J spokesman.

"We continue to fulfill our contractual obligations in relation to the Covax facility and the African Union," the company spokesman said.

J&J has projected sales of $3 billion to $3.5 billion in 2022 for its Covid-19 vaccine, much less than the $32 billion forecast by Pfizer for the same period.

But the J&J vaccine has been sought after in developing countries because, unlike other options, it does not require transportation at very cold temperatures. Also, the vaccine was originally billed as a single-shot inoculation.

Additional plants are being outfitted to make the vaccine, but production is not expected until late spring, the Times said.

H.Gonzales--AT